Additionally, STING agonist may confer an antitumor effect by suppressing CCL17 expression or CCL17-expressing cells and thereby suppressing Treg migration [7] into the tumor microenvironment (TME) (Fig.S5). The gene discussed is CCL17; the disease is neoplasm.